Perrigo announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and therapeutic equivalents for the 12 months ending August 2019 were approximately $147 million.
"I would like to thank our Quality, R&D, Operations and Regulatory teams as well as our manufacturing partner Aveva - Apotex for their dedication and professional efforts to bring this complex to manufacture product back to market,” Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan said. “This relaunch is another example of our commitment and ability to deliver specialized and complex generic products in important treatment categories to patients at more affordable prices."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!